Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Työhuone: 4124 (B-stairs, 4th floor) ORCID-tunniste: https://orcid.org/0000-0001-7478-3018 |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy TargetSenescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1CIP2A Promotes Proliferation of Spermatogonial Progenitor Cells and Spermatogenesis in Mice (2013)
- Cancer ResearchPLoS ONE
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells (2013)
- Cancer ResearchCancer Discovery
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Identification of protein interactions involved in cellular signaling (2013)
- Molecular and Cellular Proteomics
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Novel molecular markers for acute myeloid leukaemia disease activity (2013)
- European Journal of Cancer
(O2 Muu julkaisu ) - (2013)
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - 2012
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypesIdentification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. (2012)
- Oncogene
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2012)
- STEM CELLS
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2012)
- Oncogene
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Nucleolar AATF regulates c-Jun-mediated apoptosis (2012)
- Molecular Biology of the Cell
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



